



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

PEPYS

Group Art Unit: 1654

Application Serial No.: 09/985,699

Examiner: MELLER, M.V.

Filed: November 5, 2001

Title: THERAPEUTIC AGENT

September 5, 2003

* * * * *

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.56, 1.96, 1.97, and 1.98, the applicants request consideration of the documents listed on Form PTO-1449 and submitted herewith.

The applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

This Information Disclosure Statement is intended to be fully compliant with 37 C.F.R. §§1.56, 1.96, and 1.97. However, should the examiner find any part of its required content to have been omitted, the applicants earnestly solicit prompt notice to that effect, along with additional time under 37 C.F.R. §1.97(f) to enable the applicants to comply fully.

The applicants respectfully request consideration of the cited documents and making the same of record in the prosecution of the above-captioned application. The information contained in this Information Disclosure Statement is being filed under 37 C.F.R. §1.97(c), i.e., before the issuance of a final official action, a notice of allowance, or an action that closes prosecution in this application.

The fee required for the submission of this Information Disclosure Statement under 37

09/09/2003 BABRAHA1 00000002 033975 09985699

01 FC:1806 180.00 DA

30363035v1

Inventor(s): PEPYS
Application No.: 09/985,699
Attorney Docket No.: 068800-0284057

C.F.R. §1.17(p) is authorized for payment on the attached PTO/SB/17.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Thomas A. Cawley, Jr., Ph.D.

Registration No.: 40,944

Direct Telephone No.: 703-905-2144

TAC\GP

P.O. Box – 10500
McLean, VA 22102

General Telephone No.: 703-905-2000
General Facsimile No.: 703-905-2500



Atty. Dkt. No.	C-M#	Client Ref.
	068800-0284057	206002/JND/nlb
Applicant: PEPYS		
Appln. No.: 09/985,699		
Filing Date: November 5, 2001		
Examiner: MELLER, M.V.		Group Art Unit: 1654

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: September 5, 2003 Page 1 of 2

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
Examiner's Initials*	Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclosed	No
	AR1	EP 0915088	05/1999	EUROPE					
	BR1	WO 9746098	12/1997	WIPO					

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)						English Abstract		Translation Readily Available	
	CR1	PCT search report PCT/GB 02/03504							
	DR1	Lindorfer <i>et al.</i> , "A bispecific dsDNA monoclonal antibody construct for clearance of anti-dsDNA IGG in systemic lupus erythematosus", <i>J. Immunol. Methods</i> 248 , 125-138, 2001.							
	ER1	Riedstra <i>et al.</i> , "Study of an anti-human transthyretin immunoadsorbent - influence of coupling chemistry on binding capacity and ligand leakage", <i>J. Chromatogr. B: Biomedical Sciences & Applications</i> . 705(2) , 213-222, 1998.							
	FR1	Paul <i>et al.</i> , "Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates", <i>Bioorg. Med. Chem. Lett.</i> 10(18) , 2149-2152, 2000.							
	GR1	Cleaveland <i>et al.</i> , "Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program", <i>Biochem. Pharmacol.</i> 49(7) , 947-954, 1995.							
	HR1	Purkey <i>et al.</i> , "Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma", <i>Proc. Natl. Acad. Sci. USA</i> 98(10) , 5566-5571, 2001.							
	IR1	Pepys <i>et al.</i> , "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis", <i>Nature</i> 417 , 254-259, 2002.							
	JR1	Hind <i>et al.</i> , "Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits", <i>Lancet</i> , 376-378, 1984.							
	KR1	Tennent <i>et al.</i> , "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis", <i>Proc. Natl. Acad. Sci. USA</i> 92 , 299-4303, 1995.							
	LR1	Pepys <i>et al.</i> , "Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy", <i>The Nature and Origin of Amyloid Fibrils</i> , 73-89, 1996.							
	MR1	Pepys <i>et al.</i> , "Amyloid P component. A critical review.", <i>Int. J. Exp. Clin. Invest.</i> 4 , 274-295, 1997.							
	NR1	Pepys, "C-reactive protein and amyloidosis: from protein to drugs?", <i>The Lumleian Lecture</i> , 397-414.							
	OR1	Nelson <i>et al.</i> , "Serum amyloid P component in chronic renal failure and dialysis", <i>Clinica Chimica Acta</i> 200 , 191-200, 1991.							
	PR1	Booth <i>et al.</i> , "Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis", <i>Nature</i> 385 , 787-793, 1997.							
	QR1	Pepys <i>et al.</i> , "Human lysozyme gene mutations cause hereditary systemic amyloidosis", <i>Nature</i> 362 , 553-557, 1993.							
	RR1	Purkey <i>et al.</i> , "Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma", <i>Proc. Natl. Acad. Sci. USA</i> 98(10) , 5566-5571, 2001.							

Examiner	Date Considered:
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>	



Atty. Dkt. No.	C-M#	Client Ref.
	068800-0284057	206002/JND/nlb

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: PEPYS
Appln. No.: 09/985,699
Filing Date: November 5, 2001
Examiner: MELLER, M.V. Group Art Unit: 1654

Date: September 5, 2003 Page 2 of 2

Examiner's Initials*							Enclosed	No	Enclosed	No
-------------------------	--	--	--	--	--	--	----------	----	----------	----

OTHER: (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

SR1	Holmgren <i>et al.</i> , "Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met ³⁰), <i>Clin. Genet.</i> 40 , 242-246, 1991.				
TR1	Pepys <i>et al.</i> , "Isolation of amyloid P component (Protein AP) from normal serum as a calcium-dependent binding protein", <i>Lancet</i> , 1029-1031, 1977.				
UR1	Pontet <i>et al.</i> , "One step preparation of both human C-reative protein and Cit", <i>FEBS Letters</i> 88(2) , 172-175, 1978.				
VR1	Hind <i>et al.</i> , "Binding specificity of serum amyloid P component for the pyruvate acetal of galactose", <i>J. Exp. Med.</i> 159 , 1058-1069, 1984.				
WR1	Emsley <i>et al.</i> , "Structure of pentameric human serum amyloid P component", <i>Nature</i> 367 , 338-345, 1994.				
XR1	Hohenester <i>et al.</i> , "Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP", <i>J. Mol. Biol.</i> 269 , 570-578, 1997.				
YR1	Ashton <i>et al.</i> , "Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses", <i>J. Mol. Biol.</i> 272 , 408-422, 1997.				
ZR1	Baltz <i>et al.</i> , "Calcium-dependent aggregation of human serum amyloid P component", <i>Biochim. Biophys. Acta</i> 701 , 229-236, 1982.				
AR2	Booth <i>et al.</i> , "Analysis of autoaggregation and ligand binding sites of serum amyloid P component by in vitro mutagenesis", <i>Amyloid and Amyloidosis 1998</i> , 23-25, 1998.				
BR2	Hutchinson <i>et al.</i> , "Human serum amyloid P component is a single uncomplexed pentamer in whole serum", <i>Mol. Med.</i> 6(6) , 482-493, 2000.				
CR2	Hawkins <i>et al.</i> , "Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis", <i>J. Clin. Invest.</i> 86 , 1862-1869, 1990.				
DR2	Hutchinson <i>et al.</i> , "The petraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes <i>in vivo</i> ", <i>J. Clin. Invest.</i> 94 , 1390-1396, 1994.				
ER2	Pepys <i>et al.</i> , "Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure", <i>Proc. Natl. Acad. Sci. USA</i> 91 , 5602-5606, 1994.				
FR2	Holmgren <i>et al.</i> , "Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis", <i>Lancet</i> , 1113-1116, 1993.				
GR2	Klabunde <i>et al.</i> , "Rational design of potent human transthyretin amyloid disease inhibitors", <i>Nature Struct. Biol.</i> 7(4) , 312-321, 2000.				

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.